PAR-25-072: Pragmatic Trials across the Cancer Control Continuum (UG3 . . . Specifically, this NOFO will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design This NOFO will use the UG3 UH3 phased cooperative agreement mechanism
Pragmatic Trials across the Cancer Control Continuum (UG3 UH3 Clinical . . . Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design This FOA will use the UG3 UH3 phased cooperative agreement mechanism
Memorial Sloan Kettering Awarded Prestigious NCI Grant to Further . . . A team at Memorial Sloan Kettering Cancer Center (MSK) led by thoracic surgeon Prasad Adusumilli, MD, has been awarded a distinguished UG3 UH3 grant from the National Cancer Institute (NCI) to advance research and testing of chimeric antigen receptor (CAR) T cell therapy for solid tumors
Pragmatic Trials across the Cancer Control Continuum (Clinical Trials . . . use the UG3 UH3 phased cooperative agreement mechanism The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase Cancer-related Intervention: An action taken to affect one or more cancer-related outcomes
Cancer Immunoprevention Network (CIP-Net) - NCI - National Cancer Institute New UG3 UH3 grants for CIP-Net were awarded in Summer 2024 Drs Madhav Dhodapkar, Richard Flavell, and Noah Palm with the Emory University CIP-Net Project are investigating and targeting microbial triggers of monoclonal gammopathy of undetermined significance (a precursor state to multiple myeloma) for immunoprevention
PAR-25-170 Digital Health Technology Derived Biomarkers and Outcome . . . First Phase (UG3; 1-2 years): Optimize and finalize protocols to ensure standardization across the sites and target populations; take into consideration missing data, amount of wear use time needed for planned analyses in the prospective longitudinal clinical validation study (UH3 phase)
Pragmatic Trials across the Cancer Control Continuum (UG3 UH3 Clinical . . . Specifically, this NOFO will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design This NOFO will use the UG3 UH3 phased cooperative agreement mechanism